This report utilized data from ADNI12 (http://adni.loni.ucla.edu/), a multi-site longitudinal study that was launched in 2004 as a public-private partnership. The initial phase (ADNI-1) enrolled individuals aged 55–90 years who were recruited from over 50 sites across the United States and Canada and followed at 6-to 12-month intervals for 2–3 years. These individuals included approximately 200 healthy controls (HC), 400 patients with late MCI (LMCI), and 200 patients clinically diagnosed with probable AD. Subsequent phases (ADNI-GO and ADNI-2) have extended follow-up for existing participants and have enrolled additional individuals, including those meeting criteria for early MCI (EMCI). All participants provided written informed consent and study protocols were approved by each site’s institutional review board. Further information about ADNI, including full study protocols, complete inclusion and exclusion criteria, and data collection and availability can be found at http://www.adni-info.org/.
